CARLSBAD, Calif.--(BUSINESS WIRE)--Invitrogen Corporation (NASDAQ:IVGN), a leading provider of essential life sciences technologies for research, production and diagnostics, today announced the availability of a proprietary test kit that enables better screening for cardiotoxicity traits of potential drug compounds earlier in the discovery process. The Predictor™ hERG Fluorescence Polarization Assay Kit is the first commercially available non-radioactive, homogenous assay kit for high-throughput screening of compounds interacting with the hERG ion channel.
